Does VRDN pay dividends?

Viridian Therapeutics Inc (VRDN) does not currently pay a regular dividend.

What is VRDN's market cap?

Viridian Therapeutics Inc (VRDN) has a market capitalization of $2.62B with a current stock price of $23.16.

Viridian Therapeutics Inc (VRDN)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$23.16

+0.08 (+0.35%)

Market Cap: $2.62B

Last updated: Sep 01, 2026 at 5:00 PM ET

Earnings

Performance (10Y)

Beat Rate

51%(20/39)

Avg Surprise

-85.37%

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.99

Range$-1.50 - $-0.37

11 analysts

EPS Revisions

30d

EPS Estimate Drift

90d ago$-1.00-1.3%

60d ago$-0.98+0.5%

30d ago$-0.93+6.3%

7d ago$-0.93+6.3%

Current$-0.99

Revenue Consensus

$9M

Range$0 - $79M

14 analysts

Period ending Dec 31, 2026

EPS Consensus$-0.86

Range$-2.18 - $-0.09

12 analysts

Revenue Consensus

$18M

Range$959960 - $100M

14 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.86	$-2.18 - $-0.09	-	-	12	-	-
Sep 30, 2026Sep 26EST	-	$-0.99	$-1.50 - $-0.37	-	-	11	2 6 30d	-
Jun 30, 2026Jun 26 Reported Aug 5, 2026Reported Aug 5	$-1.05	$-0.97	$-1.22 - $-0.87	-8.25%	Miss	11	3 2 30d	-5.0%
Mar 31, 2026Mar 26 Reported May 5, 2026Reported May 5	$-0.90	$-1.08	$-1.29 - $-0.94	+16.67%	Beat	11	0 1 30d	-3.4%
Dec 31, 2025Dec 25 Reported Feb 26, 2026Reported Feb 26	$-1.08	$-0.90	$-1.32 - $-0.59	-20.00%	Miss	12	0 2 30d	-33.3%
Sep 30, 2025Sep 25 Reported Nov 5, 2025Reported Nov 5	$-0.34	N/A	-	+58.54%	Beat	10	1 3 30d	+70.4%
Jun 30, 2025Jun 25 Reported Aug 6, 2025Reported Aug 6	$-1.00	$-0.98	$-1.09 - $-0.81	-2.04%	Miss	12	3 5 30d	+2.0%
Mar 31, 2025Mar 25 Reported May 6, 2025Reported May 6	$-0.87	$-0.96	$-1.28 - $-0.84	+9.38%	Beat	9	3 1 30d	-10.1%
Dec 31, 2024Dec 24 Reported Feb 27, 2025Reported Feb 27	$-0.81	$-1.04	$-1.20 - $-0.84	+22.43%	Beat	12	1 6 30d	+40.0%
Sep 30, 2024Sep 24 Reported Nov 12, 2024Reported Nov 12	$-1.15	$-1.05	$-1.17 - $-0.80	-9.52%	Miss	14	No revisions (30d)	-5.5%
Jun 30, 2024Jun 24 Reported Aug 8, 2024Reported Aug 8	$-1.02	$-0.92	$-1.14 - $-0.69	-10.87%	Miss	15	No revisions (30d)	+19.7%
Mar 31, 2024Mar 24 Reported May 8, 2024Reported May 8	$-0.79	$-1.10	$-1.36 - $-0.81	+28.18%	Beat	12	No revisions (30d)	+50.9%
Dec 31, 2023Dec 23 Reported Feb 27, 2024Reported Feb 27	$-1.35	$-1.03	$-1.17 - $-0.84	-31.07%	Miss	13	No revisions (30d)	-19.5%
Sep 30, 2023Sep 23 Reported Nov 13, 2023Reported Nov 13	$-1.09	$-1.24	$-1.44 - $-0.91	+12.10%	Beat	14	No revisions (30d)	-26.7%
Jun 30, 2023Jun 23 Reported Aug 8, 2023Reported Aug 8	$-1.27	$-1.26	$-1.69 - $-0.97	-0.79%	Miss	14	1 0 30d	-19.8%
Mar 31, 2023Mar 23 Reported May 9, 2023Reported May 9	$-1.61	$-1.02	$-1.23 - $-0.82	-57.84%	Miss	10	No revisions (30d)	-64.3%
Dec 31, 2022Dec 22 Reported Mar 8, 2023Reported Mar 8	$-1.13	$-0.72	$-0.94 - $-0.50	-56.94%	Miss	10	No revisions (30d)	+14.4%
Sep 30, 2022Sep 22 Reported Nov 14, 2022Reported Nov 14	$-0.86	$-1.01	$-1.24 - $-0.48	+14.85%	Beat	8	No revisions (30d)	+31.2%
Jun 30, 2022Jun 22 Reported Aug 15, 2022Reported Aug 15	$-1.06	$-0.90	$-1.05 - $-0.51	-17.78%	Miss	7	No revisions (30d)	+52.0%
Mar 31, 2022Mar 22 Reported May 12, 2022Reported May 12	$-0.98	$-1.08	$-1.32 - $-0.90	+9.26%	Beat	5	No revisions (30d)	+66.3%
Dec 31, 2021Dec 21 Reported Mar 10, 2022Reported Mar 10	$-1.32	$-0.99	$-1.43 - $-0.33	-33.33%	Miss	7	No revisions (30d)	+95.7%
Sep 30, 2021Sep 21 Reported Nov 4, 2021Reported Nov 4	$-1.25	$-1.34	$-2.29 - $-0.26	+6.72%	Beat	6	No revisions (30d)	+16.7%
Jun 30, 2021Jun 21 Reported Aug 11, 2021Reported Aug 11	$-2.21	$-1.40	$-2.65 - $-0.32	-57.86%	Miss	5	No revisions (30d)	-22.8%
Mar 31, 2021Mar 21 Reported May 6, 2021Reported May 6	$-2.91	$-0.76	$-1.65 - $-0.30	-282.89%	Miss	5	No revisions (30d)	-7.8%
Dec 31, 2020Dec 20 Reported Mar 25, 2021Reported Mar 25	$-30.74	$-1.03	$-1.27 - $-0.19	-2884.47%	Miss	3	No revisions (30d)	-561.1%
Sep 30, 2020Sep 20 Reported Nov 10, 2020Reported Nov 10	$-1.50	$-1.99	-	+24.62%	Beat	-	-	+72.2%
Jun 30, 2020Jun 20 Reported Aug 5, 2020Reported Aug 5	$-1.80	$-2.47	-	+27.13%	Beat	-	-	+58.6%
Mar 31, 2020Mar 20 Reported May 7, 2020Reported May 7	$-2.70	$-2.88	-	+6.25%	Beat	-	-	+52.6%
Dec 31, 2019Dec 19 Reported Mar 11, 2020Reported Mar 11	$-4.65	$-3.78	-	-23.02%	Miss	-	-	+6.1%
Sep 30, 2019Sep 19 Reported Nov 7, 2019Reported Nov 7	$-5.40	$-4.44	-	-21.62%	Miss	-	-	-24.1%
Jun 30, 2019Jun 19 Reported Aug 7, 2019Reported Aug 7	$-4.35	$-5.45	-	+20.18%	Beat	-	-	+0.0%
Mar 31, 2019Mar 19 Reported May 8, 2019Reported May 8	$-5.70	$-5.16	-	-10.47%	Miss	-	-	-111.1%
Dec 31, 2018Dec 18 Reported Mar 13, 2019Reported Mar 13	$-4.95	$-4.62	-	-7.14%	Miss	-	-	-13.8%
Sep 30, 2018Sep 18 Reported Nov 7, 2018Reported Nov 7	$-4.35	$-4.76	-	+8.61%	Beat	-	-	-7.4%
Jun 30, 2018Jun 18 Reported Aug 7, 2018Reported Aug 7	$-4.35	$-4.35	-	+0.00%	Beat	-	-	+14.7%
Mar 31, 2018Mar 18 Reported May 9, 2018Reported May 9	$-2.70	$-3.67	-	+26.43%	Beat	-	-	+70.0%
Dec 31, 2017Dec 17 Reported Mar 14, 2018Reported Mar 14	$-4.35	$-4.76	-	+8.61%	Beat	-	-	-26.1%
Sep 30, 2017Sep 17 Reported Nov 8, 2017Reported Nov 8	$-4.05	$-5.70	-	+28.95%	Beat	-	-	-17.4%
Jun 30, 2017Jun 17 Reported Aug 11, 2017Reported Aug 11	$-5.10	$-7.05	-	+27.66%	Beat	-	-	-
Mar 31, 2017Mar 17 Reported May 10, 2017Reported May 10	$-9.00	$-3.60	-	-150.00%	Miss	-	-	-
Dec 31, 2016Dec 16 Reported Mar 24, 2017Reported Mar 24	$-3.45	$-3.45	-	+0.00%	Beat	-	-	-
Sep 30, 2016Sep 16 Reported Oct 26, 2016Reported Oct 26	$-3.45	N/A	-	N/A	Beat	-	-	-

Key Metrics

Valuation
P/E Ratio	-6.87	EV/EBITDA	-3.18x
Price/FCF	-7.46x	FCF Yield	-13.41%
Profitability
Profit Margin	0.00%	Operating Margin	-44461.00%
ROE	-65.70%	ROIC	-32.13%
Financial Health
Debt/Equity	0.37x	Interest Coverage	-19.43x
Current Ratio	16.95x	Quick Ratio	16.95x
Trading Statistics
Beta	0.94	Avg Volume	1.65M
52-Week High	$34.29	52-Week Low	$13.18

Technical Indicators Dashboard

Moving Averages

SMA 10$24.01

SMA 20$23.21

SMA 50$20.64

SMA 200$23.90

EMA 10$23.55

EMA 20$22.92

EMA 50$21.23

EMA 200$21.20

MACD

Line: 0.97Signal: 1.16Hist: -0.18

ADX

ADX: 39.8+DI: 29.0-DI: 19.9

Aroon & PSAR

Aroon Up68.0

Aroon Down20.0

PSAR$24.77

Bollinger Bands

Upper Band$25.40

Lower Band$21.02

%B Position1890%(Upper)

Band Width0.49

RSI (14-Day)

Neutral

56.3

Momentum Oscillators

Stoch %K54.1

Stoch %D66.0

Williams %R-52.5

ROC (10d)0.3%

Momentum0.07

CCI (20d)-9.0

MFI (14d)37.9

Volatility Measures

ATR (14d)$0.85(3.7%)

StdDev (20d)1.10

Hist Vol51.6%(High)

Volume Flow

VWAP$23.02

OBV10.0M

AD Line-5.4M

CMF (20d)0.207

Volume Metrics

Avg Vol (20d)1.6M

Vol Ratio0.6x

VWMA (20d)$23.01

Pivot Points

R3$24.17

R2$23.93

R1$23.51

Pivot Point$23.27

S1$22.85

S2$22.61

S3$22.19

Advanced Oscillators

TSI28.47

Ultimate Osc41.8

KST204.40

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$284,000	$141,000	$132,000	$70.57M	$75,000	$72,000	$72,000	$86,000	$72,000	$72,000	$72,000	$72,000
Cost of Revenue	$117,000	$121,000	$320,000	N/A	N/A	N/A	$123,000	N/A	$5.79M	$345,000	$350,000	$335,000
Gross Profit	$284,000	$141,000	$-188,000	$70.57M	$75,000	$72,000	$72,000	$86,000	$72,000	$72,000	$72,000	$72,000

Operating Expenses	$126.55M	$116.31M	$122.56M	$110.58M	$106.84M	$93.94M	$87.54M	$83.57M	$72.26M	$55.97M	$71.55M	$51.30M
R&D	$71.58M	$77.63M	$89.21M	$86.26M	$86.63M	$76.83M	$71.96M	$69.16M	$56.19M	$40.94M	$38.56M	$30.39M
SG&A	$54.98M	$38.68M	$33.67M	$24.32M	$20.22M	$17.10M	$15.58M	$14.41M	$16.07M	$15.03M	$32.99M	$20.91M
Operating Income	$-126,268,000	$-116,169,000	$-122,749,000	$-40,013,000	$-106,767,000	$-93,866,000	$-87,472,000	$-83,480,000	$-72,187,000	$-55,897,000	$-71,478,000	$-51,224,000

Interest Income	$8.49M	$7.87M	$7.79M	$5.52M	$6.55M	$7.54M	$8.61M	$7.79M	$7.79M	$7.94M	$5.53M	$4.16M
Interest Expense	$8.31M	$3.46M	$6.61M	$560,000	$514,000	$586,000	$858,000	$1.00M	$597,000	$587,000	$916,000	$600,000
Income Before Tax	$-127,119,000	$-104,901,000	$-120,355,000	$-34,599,000	$-100,735,000	$-86,912,000	$-79,725,000	$-76,689,000	$-64,993,000	$-48,542,000	$-66,860,000	$-47,660,000
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$72.19M	$-145,000	$5.53M	$-135,000

Net Income	$-127,119,000	$-104,901,000	$-120,355,000	$-34,599,000	$-100,735,000	$-86,912,000	$-79,725,000	$-76,689,000	$-64,993,000	$-48,542,000	$-66,860,000	$-47,660,000

EBITDA	$-118,695,000	$-101,318,000	$-114,087,000	$-33,929,000	$-100,108,000	$-86,209,000	$-78,744,000	$-75,555,000	$-64,254,000	$-47,810,000	$-65,794,000	$-46,925,000
EBIT	$-118,812,000	$-101,439,000	$-113,747,000	$-34,039,000	$-100,221,000	$-86,326,000	$-78,867,000	$-75,685,000	$-64,396,000	$-47,955,000	$-65,944,000	$-47,060,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about VRDN

News

Viridian Therapeutics, Inc. - Common Stock (Nasdaq:VRDN) Stock Quote

This article provides a stock quote for Viridian Therapeutics, Inc. (Nasdaq: VRDN), showing its current price, daily range, 52-week range, and key performance metrics. It also lists recent news and financial updates concerning the company, including FDA approvals, financial results, and investor conference participation, indicating active developments in its biopharmaceutical operations. The article also includes frequently asked questions about the company's public trading status and market capitalization.

The Chronicle-Journal•Aug 21, 2026 11:12 PM8/21/26•

Somewhat-Bullish

Viridian Therapeutics CLO Jennifer Tousignant sells $348,194 in shares

Jennifer Tousignant, Chief Legal Officer at Viridian Therapeutics, sold 14,212 shares of the company's common stock for a total of $348,194 on August 19, 2026. This transaction occurred after she acquired 10,000 shares through exercised stock options. The sale follows a recent 11% gain in VRDN shares and comes as the company received FDA approval for its thyroid eye disease treatment, Lumvoa, prompting several analysts to reiterate positive ratings.

Investing.com•Aug 21, 2026 1:10 PM8/21/26•

Neutral

260,000 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Blue Owl Capital Holdings LP

Blue Owl Capital Holdings LP recently acquired 260,000 shares of Viridian Therapeutics, Inc. (VRDN) valued at approximately $4.8 million, making it their 23rd largest holding. Despite a recent quarterly loss, the company exceeded revenue expectations, and analysts maintain a "Moderate Buy" consensus with an average price target of $38.93. Insider activity also noted a sale of shares by Jennifer Tousignant.

MarketBeat•Aug 21, 2026 8:11 AM8/21/26•

Neutral

Deep Track Capital, LP Trims Viridian Therapeutics (VRDN) Stake in Strategic Rebalancing

Deep Track Capital, LP has reduced its stake in Viridian Therapeutics Inc (VRDN) by 33.68%, selling over 1.8 million shares. This rebalancing act leaves the investment firm with a 1.08% portfolio allocation to VRDN, a clinical-stage biotechnology company focused on thyroid eye disease. Despite the reduction, Deep Track Capital maintains some confidence in Viridian's long-term prospects, even as the stock experiences volatility and financial metrics indicate challenges typical of early-stage biopharmaceutical companies.

GuruFocus•Aug 21, 2026 2:11 AM8/21/26•

Somewhat-Bearish

Viridian Therapeutics CLO Jennifer Tousignant sells $348,194 in shares

Jennifer Tousignant, Chief Legal Officer at Viridian Therapeutics, sold 14,212 company shares for a total of $348,194 on August 19, 2026, at $24.50 per share. This transaction followed her acquisition of 10,000 shares through stock options at a lower exercise price. The sales occurred as VRDN shares experienced a gain and shortly after the company received FDA approval for its thyroid eye disease treatment, Lumvoa, leading to positive analyst outlooks.

Investing.com•Aug 21, 2026 1:11 AM8/21/26•

Somewhat-Bullish

Frequently Asked Questions About VRDN

Does VRDN pay dividends?: Viridian Therapeutics Inc (VRDN) does not currently pay a regular dividend.
What is VRDN's market cap?: Viridian Therapeutics Inc (VRDN) has a market capitalization of $2.62B with a current stock price of $23.16.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In